PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 14, 2026Urology Practice0 citations

Utility of 18 F-Flotufolastat PET/CT Imaging in High-Risk Prostate Cancer in a Real-World Setting

View Full Paper
ZTZachariah TaylorKMKayla G MeyerNSNachum Stollman

Key Points

  • To evaluate the effectiveness of PSMA PET/CT imaging with 18F-flotufolastat in upstaging high-risk prostate cancer cases.
  • Conducted in a real-world setting
  • Evaluated high-risk prostate cancer patients
  • Compared results of PSMA PET/CT to conventional imaging
  • Nearly one-third of patients experienced clinical upstaging
  • Most patients saw significant treatment changes as a result

Abstract

PSMA PET/CT with 18F-flotufolastat led to clinical upstaging in nearly one-third of men with high-risk prostate cancer and negative conventional imaging, resulting in significant treatment change in most patients. These findings support the integration of PSMA-targeted imaging into initial staging pathways for men with high-risk prostate cancer.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Taylor et al. (2026) studied this question.

synapsesocial.com/papers/696718c687ba607552bb8b16https://doi.org/10.1097/upj.0000000000000971
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sequential flotufolastat-F18 PSMA-PET scans to enhance detection of prostate cancer in patients with early PSA recurrence following radical prostatectomy.2026
  2. 2Diagnostic performance of 18 F-flotufolastat PET/CT compared with conventional imaging for detection of pelvic lymph node metastases in men with newly diagnosed prostate cancer: Descriptive post-hoc analysis from the phase 3 LIGHTHOUSE study.2026
  3. 3[ 18 F]Flotufolastat PET/MRI in Patients with Suspected Prostate Cancer: Correlation with Histopathologic Biopsy Results2025 · 1 citations
  4. 4Detection of bone metastases in men with low PSA biochemical recurrence of prostate cancer with 18 F-flotufolastat PET/CT: A post-hoc analysis from the phase 3 SPOTLIGHT study.2026
  5. 518 F-PSMA PET/CT Versus 18 F-NaF PET/CT for Staging and Treating Newly Diagnosed High-Risk Prostate Cancer: A Prospective Single-Center Study2025 · 3 citations